Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Aureka Biotechnologies raises US$100 million in Series B funding led by Granite Asia and strategic investors. The funds will enhance their AI-driven drug discovery models and research.

PRIVATEAug 11, 2026•about 3 hours ago

Amount Raised

$100 Million

Round Type

Series B

BiotechnologyTherapeutics

Investors

Nrl CapitalMp CiHigh Light CapitalGranite Asia

Description

Aureka Biotechnologies announced the close of a US$100 million Series B financing on Aug. 10, 2026. Granite Asia funded the first tranche exclusively, while a prominent strategic investor led a subsequent tranche. Participation also came from HighLight Capital and existing shareholders including MPCi and NRL Capital

Company Information

Company

Aureka Biotechnologies

About

Aureka Biotechnologies is focused on developing generative antibody drugs through three core technology platforms: a generative intelligence platform, a yeast intracellular directed evolution platform, and a microfluidic single-cell screening platform. The company aims to create a data-driven model that enhances the efficiency of antibody drug development, significantly increasing the number of breakthrough pipelines. Aureka's innovative approach incorporates autonomous agents to lead design hypotheses, redefining traditional drug development methodologies. This positions the company as a leader in addressing the shortcomings of conventional antibody drug design.

Predictive Intelligence
Strategic

ML-powered predictions for Aureka Biotechnologies's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.